Cerulean Pharma Inc. Reports Third Quarter 2015 Corporate Highlights And Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an update on corporate activities during the quarter ended September 30, 2015.

“During the third quarter, we strengthened our management team by appointing Adrian Senderowicz as Chief Medical Officer. Adrian’s experience in the lab and clinic at NCI, as a team leader at FDA, in clinical development at AstraZeneca, leading the oncology regulatory group at Sanofi, as CMO of Tokai and Ignyta, and as a board member of Puma Biotechnology make him well suited to lead our NDCs toward registration,” said Christopher D. T. Guiffre, President & Chief Executive Officer of Cerulean.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC